Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 70 Thousand USD | 645.13% |
| 2022 | -12.84 Thousand USD | 79.12% |
| 2021 | -61.51 Thousand USD | -103.53% |
| 2020 | 1.74 Million USD | 2972.56% |
| 2019 | -60.6 Thousand USD | -76.74% |
| 2018 | -34.28 Thousand USD | -276.8% |
| 2017 | -9100.00 USD | 52.11% |
| 2016 | -19 Thousand USD | 5.0% |
| 2015 | -20 Thousand USD | -121.05% |
| 2014 | 95 Thousand USD | 0.0% |
| 2013 | 95 Thousand USD | -39.1% |
| 2012 | 156 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 100.0% |
| 2008 | -25.92 Million USD | -16.47% |
| 2007 | -22.26 Million USD | -24.25% |
| 2006 | -17.91 Million USD | -37.32% |
| 2005 | -13.04 Million USD | -24.58% |
| 2004 | -10.47 Million USD | -35010.0% |
| 2003 | 30 Thousand USD | -91.03% |
| 2002 | 334.51 Thousand USD | -95.99% |
| 2001 | 8.35 Million USD | 10343.86% |
| 2000 | 79.96 Thousand USD | 391.38% |
| 1999 | 16.27 Thousand USD | -91.86% |
| 1998 | 200 Thousand USD | 100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | -66.67% |
| 1994 | 300 Thousand USD | 200.0% |
| 1993 | 100 Thousand USD | 0.0% |
| 1992 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q4 | - USD | -100.0% |
| 2023 FY | 70 Thousand USD | 645.13% |
| 2023 Q3 | 70 Thousand USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | -12.84 Thousand USD | 16.51% |
| 2022 Q2 | - USD | 100.0% |
| 2022 FY | -12.84 Thousand USD | 79.12% |
| 2021 Q4 | -15.38 Thousand USD | -0.03% |
| 2021 Q2 | -15.37 Thousand USD | 0.01% |
| 2021 FY | -61.51 Thousand USD | -103.53% |
| 2021 Q3 | -15.37 Thousand USD | 0.01% |
| 2021 Q1 | -15.37 Thousand USD | 99.12% |
| 2020 Q3 | - USD | -100.0% |
| 2020 FY | 1.74 Million USD | 2972.56% |
| 2020 Q1 | 340.85 Thousand USD | 0.0% |
| 2020 Q2 | 1.4 Million USD | 310.73% |
| 2020 Q4 | -1.74 Million USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 FY | -60.6 Thousand USD | -76.74% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | 51 Thousand USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | -34.28 Thousand USD | -276.8% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | -9100.00 USD | 52.11% |
| 2017 Q4 | 285 Thousand USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | -19 Thousand USD | 5.0% |
| 2016 Q1 | 83 Thousand USD | -81.88% |
| 2016 Q2 | - USD | -100.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | 458 Thousand USD | 0.0% |
| 2015 FY | -20 Thousand USD | -121.05% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | -146 Thousand USD | 0.0% |
| 2014 FY | 95 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q3 | 95 Thousand USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 Q4 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 95 Thousand USD | -39.1% |
| 2012 FY | 156 Thousand USD | 0.0% |
| 2012 Q1 | 114 Thousand USD | 0.0% |
| 2012 Q2 | - USD | -100.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | 42 Thousand USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 100.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | -100.0% |
| 2009 FY | - USD | 100.0% |
| 2009 Q1 | 296 Thousand USD | 101.14% |
| 2009 Q4 | -31.15 Million USD | 0.0% |
| 2008 Q3 | 13 Thousand USD | 0.0% |
| 2008 Q1 | - USD | 100.0% |
| 2008 FY | -25.92 Million USD | -16.47% |
| 2008 Q4 | -25.94 Million USD | -199646.15% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q4 | -22.26 Million USD | 0.0% |
| 2007 Q3 | - USD | -100.0% |
| 2007 FY | -22.26 Million USD | -24.25% |
| 2007 Q1 | - USD | 100.0% |
| 2007 Q2 | 7000.00 USD | 0.0% |
| 2006 FY | -17.91 Million USD | -37.32% |
| 2006 Q4 | -10.48 Million USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 100.0% |
| 2006 Q1 | -2.42 Million USD | 73.93% |
| 2005 Q1 | - USD | 100.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | -9.28 Million USD | 0.0% |
| 2005 FY | -13.04 Million USD | -24.58% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q1 | 7000.00 USD | 100.47% |
| 2004 FY | -10.47 Million USD | -35010.0% |
| 2004 Q4 | -12.64 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | -100.0% |
| 2003 Q1 | 20 Thousand USD | 100.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2003 FY | 30 Thousand USD | -91.03% |
| 2003 Q4 | -1.49 Million USD | 0.0% |
| 2002 Q3 | 73 Thousand USD | 2.82% |
| 2002 Q1 | 79 Thousand USD | -98.92% |
| 2002 FY | 334.51 Thousand USD | -95.99% |
| 2002 Q4 | -1.16 Billion USD | -1591196.55% |
| 2002 Q2 | 71 Thousand USD | -10.13% |
| 2001 Q4 | 7.31 Million USD | 2744.61% |
| 2001 Q1 | 176 Thousand USD | 148.75% |
| 2001 Q3 | 257 Thousand USD | -14.05% |
| 2001 Q2 | 299 Thousand USD | 69.89% |
| 2001 FY | 8.35 Million USD | 10343.86% |
| 2000 Q4 | -361.03 Thousand USD | -187.42% |
| 2000 Q2 | 283 Thousand USD | 2258.33% |
| 2000 FY | 79.96 Thousand USD | 391.38% |
| 2000 Q1 | 12 Thousand USD | 106.53% |
| 2000 Q3 | 413 Thousand USD | 45.94% |
| 1999 Q3 | 200 Thousand USD | 100.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 FY | 16.27 Thousand USD | -91.86% |
| 1999 Q4 | -183.72 Thousand USD | -191.86% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 200 Thousand USD | 100.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q4 | - USD | -100.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1995 Q2 | 100 Thousand USD | 0.0% |
| 1995 Q4 | - USD | -100.0% |
| 1995 Q3 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | -66.67% |
| 1995 Q1 | 100 Thousand USD | -50.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 FY | 300 Thousand USD | 200.0% |
| 1994 Q4 | 200 Thousand USD | 100.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 Q3 | - USD | -100.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q2 | 100 Thousand USD | 0.0% |
| 1992 Q3 | 100 Thousand USD | 0.0% |
| 1992 Q4 | - USD | -100.0% |
| 1992 Q1 | 100 Thousand USD | 0.0% |
| 1992 FY | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2970.029% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.402% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 121.909% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.941% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.271% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 245.051% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 156.338% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.533% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -2156.609% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.285% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -6.5% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 304.978% |
| Mesoblast Limited | -35.16 Million USD | 100.199% |
| Marizyme, Inc. | 457.7 Thousand USD | 84.706% |
| Genus plc | 178.7 Million USD | 99.961% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.968% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -12.493% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 82.934% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 736.364% |
| ContraFect Corporation | -154 Thousand USD | 145.455% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 240.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 8.808% |
| IMV Inc. | -962.29 Thousand USD | 107.274% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 118.064% |
| MultiCell Technologies, Inc. | 49.32 USD | -141830.251% |
| ONE Bio Corp. | 20.12 Million USD | 99.652% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.826% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -43.149% |
| Q BioMed Inc. | -8988.00 USD | 878.816% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.752% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 553.838% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.842% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 106.132% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1513.57% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 50.178% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 171.784% |
| GB Sciences, Inc. | -624.00 USD | 11317.949% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 181.369% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 33753.846% |
| Enzolytics Inc. | 30.7 Thousand USD | -127.954% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 85.49% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 113.605% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 88.662% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.983% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 890.425% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 183.483% |
| Kadimastem Ltd | -630.13 Thousand USD | 111.109% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 92.915% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.272% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.546% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 691.466% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 60.353% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 60.353% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 94.842% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 341.379% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 84.446% |
| SYBLEU INC | 11.69 Thousand USD | -498.495% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.481% |
| Bioxytran, Inc. | -8285.00 USD | 944.9% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 118.767% |
| Neutra Corp. | 14.33 Thousand USD | -388.315% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 185.366% |
| PureTech Health plc | -1.6 Million USD | 104.367% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 106.991% |
| IXICO plc | 3.27 Million USD | 97.859% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 110.086% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 103.908% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -288.889% |